Previous close | 95.68 |
Open | 96.46 |
Bid | 94.08 x N/A |
Ask | 98.90 x N/A |
Day's range | 95.91 - 96.61 |
52-week range | 79.36 - 233.50 |
Volume | |
Avg. volume | 511,134 |
Market cap | 221.238B |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | 30.06 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.20 (3.78%) |
Ex-dividend date | 09 Mar 2023 |
1y target est | N/A |
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.